Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.
Immune checkpoint inhibitor
pembrolizumab
pleomorphic carcinoma
sarcomatoid carcinoma
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
20
01
2021
revised:
08
02
2021
accepted:
09
02
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
We report, herein, three cases of pleomorphic carcinoma of the lung treated with immune checkpoint inhibitors. Case 1: A 73-year-old man was diagnosed as having pleomorphic carcinoma of the lung and treated with pembrolizumab alone. However, he showed no response and died 4 months after the initiation of the treatment. Case 2: A 66-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on a combination regimen of pembrolizumab plus carboplatin plus nab-paclitaxel, and a remarkable response was observed. Case 3: A 49-year-old man was diagnosed as having pleomorphic carcinoma of the lung. He was started on pembrolizumab monotherapy as second-line treatment. Eleven months after the treatment initiation, computed tomography revealed the decrease of tumor diameter. Immune checkpoint inhibitor therapy is expected to improve the prognosis of patients with pleomorphic carcinoma of the lung.
Identifiants
pubmed: 33910853
pii: 35/3/1687
doi: 10.21873/invivo.12428
pmc: PMC8193335
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Carboplatin
BG3F62OND5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1687-1692Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Cancer. 2015 Nov;51(17):2698-707
pubmed: 26329973
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Int Cancer Conf J. 2017 Dec 15;7(2):43-47
pubmed: 31149513
Anticancer Res. 2019 Dec;39(12):6887-6893
pubmed: 31810958
Cancer Immunol Immunother. 2021 Feb;70(2):337-348
pubmed: 32757055
Anticancer Res. 2017 Oct;37(10):5857-5862
pubmed: 28982912
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Clin Case Rep. 2018 May 29;6(7):1338-1341
pubmed: 29988633
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
Cancer Immunol Res. 2020 Mar;8(3):334-344
pubmed: 31871122
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
JAMA Oncol. 2018 Mar 1;4(3):351-357
pubmed: 29327044
JCI Insight. 2016 May 5;1(6):
pubmed: 27182556
Eur J Cancer. 2020 Jun;132:150-158
pubmed: 32371248
Thorac Cancer. 2017 Nov;8(6):724-728
pubmed: 28881488
Int J Mol Sci. 2019 Apr 02;20(7):
pubmed: 30986912
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
BMC Res Notes. 2015 Dec 18;8:800
pubmed: 26682906
Lung Cancer. 2007 Oct;58(1):112-5
pubmed: 17574296
Eur J Cancer. 2016 Jun;60:125-35
pubmed: 27107327
In Vivo. 2020 May-Jun;34(3):1439-1443
pubmed: 32354943
Intern Med. 2019 Apr 1;58(7):985-989
pubmed: 30568113
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Oncotarget. 2017 Oct 7;8(61):103117-103128
pubmed: 29262550
Med Oncol. 2009;26(3):287-91
pubmed: 18989796
J Thorac Oncol. 2015 Sep;10(9):1243-1260
pubmed: 26291008